NMS-873
Based on 19 publication(s) in Google Scholar
NMS-873 is a potent, selective allosteric VCP/p97 inhibitor with an IC50 value of 30 nM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.92%
- CAS No.: 1418013-75-8
- Formule: C27H28N4O3S2
- Masse moléculaire:520.67
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) NMS-873
More- Signal Transduct Target Ther. 2025 Jan 24;10(1):26. [Abstract]
- Neuron. 2025 Aug 29:S0896-6273(25)00587-2. [Abstract]
- Mol Cell. 2020 Jul 16;79(2):320-331.e9. [Abstract]
- J Immunother Cancer. 2025 Nov 19;13(11):e012652. [Abstract]
- Phytomedicine. 2026 Jun:155:158094. [Abstract]
- Cell Chem Biol. 2019 Sep 19;26(9):1306-1314.e5. [Abstract]
- EMBO Mol Med. 2022 Jul 7;14(7):e15373. [Abstract]
- Cell Rep. 2024 Jun 27;43(7):114402. [Abstract]
- Cell Oncol (Dordr). 2026 Jan 8;49(1):21. [Abstract]
- Inflammation. 2024 Oct;47(5):1868-1883. [Abstract]
- J Cell Mol Med. 2016 Jan;20(1):58-70. [Abstract]
- FASEB J. 2025 May 15;39(9):e70585. [Abstract]
- J Biol Chem. 2022 Jun;298(6):101936. [Abstract]
- Vet Microbiol. 2022 Sep:272:109511. [Abstract]
- bioRxiv. 2026 Mar 13.
- bioRxiv. 2026 Feb 18:2026.02.17.706203. [Abstract]
- Biomed Pharmacother. 2025 Sep 18:192:118565. [Abstract]
- bioRxiv. 2024 June 12.
- bioRxiv. 2023 Aug 30:2023.08.30.555637. [Abstract]
Customer Validation & Images
-
WB
-
WB
-
WB
-
Cell Imaging/Staining
-
WB
Activité biologique
IC50: 30 nM[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BTI-TN-5B1-4 | IC50 |
0.024 μM
Compound: 116
|
Inhibition of human recombinant His-GST tagged VCP expressed in baculovirus infected Hi5 cells assessed as ADP formation incubated for 20 mins proir to substrate addition measured after 90 mins by NADH coupled assay
Inhibition of human recombinant His-GST tagged VCP expressed in baculovirus infected Hi5 cells assessed as ADP formation incubated for 20 mins proir to substrate addition measured after 90 mins by NADH coupled assay
|
[PMID: 23245311] |
| HCT-116 | IC50 |
0.38 μM
Compound: 116
|
Cytotoxicity against human HCT116 cells after 72 hrs by luciferase reporter gene assay
Cytotoxicity against human HCT116 cells after 72 hrs by luciferase reporter gene assay
|
[PMID: 23245311] |
| HCT-116 | IC50 |
0.45 μM
Compound: 32; NMS-873
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability
|
[PMID: 36893622] |
| L929 | IC50 |
1.3 nM
Compound: 32; NMS-873
|
Antiproliferative activity against mouse L929 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay
Antiproliferative activity against mouse L929 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay
|
[PMID: 36893622] |
| U-87MG ATCC | IC50 |
6214.67 nM
Compound: NMS-873
|
Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay
Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay
|
[PMID: 36634454] |
NMS-873 has antiproliferative effect on a panel of tumor cell lines with IC50 values in the range of 0.08 μM to 2 μM. For HCT116 and HeLa cells, the IC50 values are 0.4 μM and 0.7 μM, respectively. NMS-873 reduces VCP sensitivity to trypsin digestion, preventing degradation of the linker-D2 domain. NMS-873 induces clear, dose-dependent accumulation of poly-Ub proteins and stabilization of cyclin E and Mcl-1 at doses consistent with its antiproliferative IC50 value[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1418013-75-8
-
Appearance Solid
-
Masse moléculaire 520.67
-
Formule C27H28N4O3S2
-
Color Off-white to yellow
-
SMILES
CC(C=C(OCC1=NN=C(SC2CCCC2)N1C3=CC=CN=C3)C=C4)=C4C5=CC=C(S(=O)(C)=O)C=C5
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (19)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
VCP downstream metabolite glycerol-3-phosphate (G3P) inhibits CD8+T cells function in the HCC microenvironment. [Abstract]2025 Jan 24;10(1):26. PMID: 39848960
NMS-873 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jan 24;10(1):26. [Abstract]
Immunoblot analysis of the indicated proteins in HCCLM3 cells treated with gradient concentrations of NMS-873 (4-8 μM) or Vehicle for 18h.
-
Neuron
2025 Aug 29:S0896-6273(25)00587-2. PMID: 40902597 -
Mol Cell
RNF126-Mediated Reubiquitination Is Required for Proteasomal Degradation of p97-Extracted Membrane Proteins. [Abstract]2020 Jul 16;79(2):320-331.e9. PMID: 32645369
NMS-873 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2020 Jul 16;79(2):320-331.e9. [Abstract]
Inhibition of E1 activity impairs degradation of retrotranslocated ABCG2-F208S. Cells expressing FLAG-tagged ABCG2-F208S and myc-tagged ubiquitin were pretreated for 1 h with NMS-873 (10 μM) and z-VAD (60 μM) and then chased with z-VAD, CHX, and either MG132 (20 μM) or MLN7243 (10 μM). The cells were semipermeabilized at 0 and 2 h with digitonin. The cytosolic and membrane fractions were analyzed by immunoblotting for indicated proteins either directly or after anti-FLAG immunoprecipitations (IPs). Arrowheads denote glycosylated ABCG2-F208S extracted from the ER. Samples IPed from the cytosolic fraction were either left untreated or digested with the endoglycosidase H (bottom)
-
J Immunother Cancer
2025 Nov 19;13(11):e012652. PMID: 41260904 -
Phytomedicine
Self-assembly of glycyrrhizic acid and aconitine alleviates heart failure by inhibiting autophagy and inducing reprogramming of energy metabolism. [Abstract]2026 Jun:155:158094. PMID: 41886950 -
Cell Chem Biol
6-Phosphogluconate Dehydrogenase Links Cytosolic Carbohydrate Metabolism to Protein Secretion via Modulation of Glutathione Levels. [Abstract]2019 Sep 19;26(9):1306-1314.e5. PMID: 31204288
NMS-873 purchased from MedChemExpress. Usage Cited in: Cell Chem Biol. 2019 Sep 19;26(9):1306-1314.e5. [Abstract]
Representative WM793 cells using (A) light microscopy and (B) electron microscopy. The treatments include brefeldin A (1 μM, 36 h), 6AN (20 μM, 48 h), and NMS-873 (5 μM, 18 h).
NMS-873 purchased from MedChemExpress. Usage Cited in: Cell Chem Biol. 2019 Sep 19;26(9):1306-1314.e5. [Abstract]
Immunoblots of HSPA5 (Bip) and spliced XBP1 (XBP1s) in WM793 cells treated with brefeldin A (1 μM, 36h), 6AN (20 μM, 48h), or NMS873 (5 μM, 18h).
-
EMBO Mol Med
Sigma-1 receptor attenuates osteoclastogenesis by promoting ER-associated degradation of SERCA2. [Abstract]2022 Jul 7;14(7):e15373. PMID: 35611810
NMS-873 purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2022 Jul 7;14(7):e15373. [Abstract]
Western blots showing SERCA2 expression in HEK‐293T cells with or without Sigmar1 co‐transfection treated with NMS‐873 (0.25-1 μM) at the indicated concentration. All inhibitors were applied to cells 8 h prior to protein collection.
-
Cell Rep
Translocational attenuation mediated by the PERK-SRP14 axis is a protective mechanism of unfolded protein response. [Abstract]2024 Jun 27;43(7):114402. PMID: 38943644 -
Cell Oncol (Dordr)
Targeting VCP with V8 suppresses glioblastoma development via formation of aggregates and disruption of mitophagy flux. [Abstract]2026 Jan 8;49(1):21. PMID: 41505038 -
Inflammation
2024 Oct;47(5):1868-1883. PMID: 38563877 -
J Cell Mol Med
p97/VCP promotes Cullin-RING-ubiquitin-ligase/proteasome-dependent degradation of IκBα and the preceding liberation of RelA from ubiquitinated IκBα. [Abstract]2016 Jan;20(1):58-70. PMID: 26463447
NMS-873 purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2016 Jan;20(1):58-70. [Abstract]
Efficient TNF-induced degradation of IκBα and concomitant liberation of RelA requires functional p97/VCP. Cells stimulated with TNF (10 ng/mL) for the indicated times after either pretreatment with p97/VCP inhibitor NMS-873 (2.5 μM, NMS3) for 10 min. or inhibitor treatment (2.5 μM) from 15 min. after stimulation in either the presence (NMS1) or the absence (NMS2) of pan-caspase inhibitor ZVAD-fmk (10 μM), are subjected to subcellular fractionation. LMB (10 ng/mL)
-
FASEB J
FAT1 Enhances the Sensitivity of Non-Small Cell Lung Cancer to VCP Inhibitors by Regulating the Activation of the Endoplasmic Reticulum Stress Pathway. [Abstract]2025 May 15;39(9):e70585. PMID: 40293794 -
J Biol Chem
AAA-ATPase valosin-containing protein binds the transcription factor SREBP1 and promotes its proteolytic activation by rhomboid protease RHBDL4. [Abstract]2022 Jun;298(6):101936. PMID: 35430252 -
Vet Microbiol
Valosin-containing protein (VCP/p97) is responsible for the endocytotic trafficking of classical swine fever virus. [Abstract]2022 Sep:272:109511. PMID: 35849988 -
-
bioRxiv
Nuclear tau aggregates inhibit RNA export and form by secondary seeding from cytosolic tau aggregates. [Abstract]2026 Feb 18:2026.02.17.706203. PMID: 41756918 -
Biomed Pharmacother
TME-responsive nanoparticles co-targeting VCP, NETs, and dual immune checkpoints for immune revitalization in EGFR/PD-L1/CTLA-4-driven colorectal cancer. [Abstract]2025 Sep 18:192:118565. PMID: 40972397 -
-
bioRxiv
2023 Aug 30:2023.08.30.555637. PMID: 37693404
Solvant et solubilité
DMSO : 20.5 mg/mL (39.37 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
The ATPase activity and the kinetic parameters of recombinant wild-type VCP and its mutants are evaluated by monitoring ADP formation in the reaction, using a modified NADH-coupled assay46. As ADP and NADH are ATP-competitive inhibitors of VCP ATPase activity, the standard protocol for the NADH-coupled assay is modified into a two-step procedure. In the first part, an ATP-regenerating system (40 U/mL pyruvate kinase and 3 mM phosphoenolpyruvate) recycles the ADP produced by VCP activity, keeps the substrate concentration constant (thus preventing product inhibition) and accumulates a stoichiometric amount of pyruvate. In the second part, the VCP enzymatic reaction is quenched with 30 mM EDTA and 250 μM NADH and stoichiometrically oxidized by 40 U/mL lactic dehydrogenase to reduce accumulated pyruvate. The decrease of NADH concentration is measured at 340 nm using a Tecan Safire 2 reader plate. The assay is performed in 96- or 384-well UV platesin a reaction buffer with 50 mM Hepes, pH 7.5, 0.2 mg/mL BSA, 10 mM MgCl2 and 2 mM DTT.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cells are seeded at 1,600 cells per well in 384-well white clear-bottom plates. Twenty-four hours after seeding, cells are treated with the compounds (eight dilution points, in duplicate, for each compound) and incubated for an additional 72 h at 37°C under a 5% CO2 atmosphere. Cells are then lysed, and the ATP content in each well is determined using a thermostable firefly luciferase-based assay from Promega as a measure of cell viability. IC50 values are calculated using the percentage of growth of treated cells versus the untreated control.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9206 mL | 9.6030 mL | 19.2060 mL | 48.0151 mL |
| 5 mM | 0.3841 mL | 1.9206 mL | 3.8412 mL | 9.6030 mL | |
| 10 mM | 0.1921 mL | 0.9603 mL | 1.9206 mL | 4.8015 mL | |
| 15 mM | 0.1280 mL | 0.6402 mL | 1.2804 mL | 3.2010 mL | |
| 20 mM | 0.0960 mL | 0.4802 mL | 0.9603 mL | 2.4008 mL | |
| 25 mM | 0.0768 mL | 0.3841 mL | 0.7682 mL | 1.9206 mL | |
| 30 mM | 0.0640 mL | 0.3201 mL | 0.6402 mL | 1.6005 mL |
NMS-873 Related Classifications
HY-15713 Related Classifications
Powered by Bioz